These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36574656)

  • 1. SPOP loss of function protects against tauopathy.
    Eck RJ; Kow RL; Black AH; Liachko NF; Kraemer BC
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2207250120. PubMed ID: 36574656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Poly(A) nucleases have differential impact on sut-2 dependent tauopathy phenotypes.
    Kow RL; Strovas TJ; McMillan PJ; Jacobi AM; Behlke MA; Saxton AD; Latimer CS; Keene CD; Kraemer BC
    Neurobiol Dis; 2021 Jan; 147():105148. PubMed ID: 33184027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sut-6/NIPP1 modulates tau toxicity.
    Kow RL; Black AH; Henderson BP; Kraemer BC
    Hum Mol Genet; 2023 Jul; 32(14):2292-2306. PubMed ID: 37000013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSUT2 is a determinant of susceptibility to tau neurotoxicity.
    Guthrie CR; Greenup L; Leverenz JB; Kraemer BC
    Hum Mol Genet; 2011 May; 20(10):1989-99. PubMed ID: 21355046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
    Wheeler JM; McMillan P; Strovas TJ; Liachko NF; Amlie-Wolf A; Kow RL; Klein RL; Szot P; Robinson L; Guthrie C; Saxton A; Kanaan NM; Raskind M; Peskind E; Trojanowski JQ; Lee VMY; Wang LS; Keene CD; Bird T; Schellenberg GD; Kraemer B
    Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration.
    Kow RL; Black AH; Saxton AD; Liachko NF; Kraemer BC
    Geroscience; 2022 Apr; 44(2):747-761. PubMed ID: 35122183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of MSUT-2 in tau neurotoxicity: a target for neuroprotection in tauopathy?
    Wheeler JM; Guthrie CR; Kraemer BC
    Biochem Soc Trans; 2010 Aug; 38(4):973-6. PubMed ID: 20658987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoplasmic reticulum unfolded protein response transcriptional targets of XBP-1s mediate rescue from tauopathy.
    Waldherr SM; Han M; Saxton AD; Vadset TA; McMillan PJ; Wheeler JM; Liachko NF; Kraemer BC
    Commun Biol; 2024 Jul; 7(1):903. PubMed ID: 39060347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOPA Decarboxylase Modulates Tau Toxicity.
    Kow RL; Sikkema C; Wheeler JM; Wilkinson CW; Kraemer BC
    Biol Psychiatry; 2018 Mar; 83(5):438-446. PubMed ID: 28751068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
    McMillan PJ; Benbow SJ; Uhrich R; Saxton A; Baum M; Strovas T; Wheeler JM; Baker J; Liachko NF; Keene CD; Latimer CS; Kraemer BC
    Brain; 2023 Aug; 146(8):3206-3220. PubMed ID: 36732296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential neuroprotective strategies against tauopathy.
    Wheeler JM; Guthrie CR; Kraemer BC
    Biochem Soc Trans; 2012 Aug; 40(4):656-60. PubMed ID: 22817711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
    Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
    SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of DNA glycosylases improves health and cognitive function in a C. elegans model of human tauopathy.
    Tiwari V; Buvarp E; Borbolis F; Puligilla C; Croteau DL; Palikaras K; Bohr VA
    Nucleic Acids Res; 2024 Oct; 52(18):10965-10985. PubMed ID: 39149885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUT-1 enables tau-induced neurotoxicity in C. elegans.
    Kraemer BC; Schellenberg GD
    Hum Mol Genet; 2007 Aug; 16(16):1959-71. PubMed ID: 17576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
    Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
    Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans.
    Guthrie CR; Schellenberg GD; Kraemer BC
    Hum Mol Genet; 2009 May; 18(10):1825-38. PubMed ID: 19273536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic Dendra2::tau expression allows in vivo monitoring of tau proteostasis in Caenorhabditis elegans.
    Han M; Saxton A; Currey H; Waldherr SM; Liachko NF; Kraemer BC
    Dis Model Mech; 2024 Mar; 17(3):. PubMed ID: 38469687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
    Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model.
    Guha S; Fischer S; Johnson GVW; Nehrke K
    Mol Neurodegener; 2020 Nov; 15(1):65. PubMed ID: 33168053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic nervous system degeneration in a C. elegans Tau
    Choudhary B; Mandelkow E; Mandelkow EM; Pir GJ
    Neurobiol Dis; 2018 Sep; 117():189-202. PubMed ID: 29894752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.